65,437 trials
Stage II Bladder Cancer AJCC v8 · Stage IIIA Bladder Cancer AJCC v8 · Muscle Invasive Bladder Carcinoma
Primary: Pathologic Complete Response Rate — 9 Participants
Healthy
Primary: Cardiodynamics: Placebo-corrected Change From Baseline in QT Interval Corrected Using Fridericia's Correction (QTcF) (ΔΔQTcF) for Treatments A, B, and C — 3.4; 4.4; 6.4…
Atrial Fibrillation
Primary: Primary Effectiveness Endpoint: Stroke, All Cause Death, and Systemic Embolism — 44; 41 Participants
Oncology
Primary: Safety and Tolerability of SUPLEXA in Subjects With Malignant Solid Tumour and Haematologic Malignancies. — 25; 3; 2 Participants
Aedes-borne Diseases · Dengue · Chikungunya
Primary: Number of Symptomatic Participants Testing Positive for Aedes-borne Virus Infections That Are Laboratory Confirmed or Serologically — 213; 209; 151; 146 Participants
HIV Positive · Ageing
Primary: The Prevalence of Reported Aches and Pains in the Last Month Across the 3 Age Groups — 473; 224; 188 participants
Tracheostomy · Communication · Acute/Critical Illness
Primary: Number of Participants Using SRAVI at Least Once — 31 Participants
Healthy
Primary: Part I: Percentage of Subjects With Drug-related Adverse Events — 16.7; 16.7; 0.0; 0.0 Percentage of participants
Muscle Invasive Bladder Cancer
Primary: Accuracy of the PET CT for Lymph Node Staging in Terms of Sensitivy Rate — 21 Participants
Chronic Hepatitis D Infection
Primary: Pharmacokinetic (PK) Parameter for Bulevirtide (BLV): AUCtau — 94.6; 112; 1880; 1810 hours(h)*nanograms per milliliter(ng/mL)
Single Ventricle Heart Disease
Primary: Effect of Udenafil 87.5 mg BID Treatment on Liver Stiffness in Udenafil Continuation and Naive Groups After 52 Weeks, as Determined by Ultrasound Shear Wave Elastography…
Acne
Primary: Percent Change in Sebum Production in Treated Sites as Compared to Baseline Using Sebutape Measurements. — -10.9; 6.9; 7.8; 45.0 Percent change from baseline
Chronic Leukemia · Hematopoietic and Lymphoid System Neoplasm · Lymphoma
Primary: Feasibility of Intervention — 41; 17; 11; 5 Participants
Eosinophilic Gastroenteritis
Primary: Change From Baseline in Mean Number of Peak Eosinophils (Eos) Count Per High-power Field (Hpf) in Gastrointestinal (GI) Biopsies — -100.4; 122.8 Peak # of eosinophils…
Healthy · Renal Insufficiency
Primary: Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib in Plasma — 19770…